This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
by Zacks Equity Research
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
KYMRNegative Net Change SNYPositive Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.
PRGOPositive Net Change ALTPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechs
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
by Zacks Equity Research
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
SRPTNegative Net Change RHHBYPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
by Zacks Equity Research
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
RVMDPositive Net Change BMYPositive Net Change MRKPositive Net Change SMMTPositive Net Change
biotechs earnings medical pharmaceuticals
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
by Zacks Equity Research
Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.
VTRSPositive Net Change RGENPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
by Zacks Equity Research
Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
EXELPositive Net Change RHHBYPositive Net Change MRKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
by Zacks Equity Research
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
EDITPositive Net Change RGENPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
by Zacks Equity Research
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
IMVTNegative Net Change ALTPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechs
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
by Zacks Equity Research
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
MIRMPositive Net Change INCYPositive Net Change RGENPositive Net Change LQDANegative Net Change
biotechs earnings
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
RXRXPositive Net Change RHHBYPositive Net Change RGENPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals